Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

The most common side effects of LIBTAYO when used alone include tiredness, muscle or bone pain, rash, diarrhea, and low levels of red blood cells (anemia). The most common side effects of LIBTAYO ...

The most common side effects of LIBTAYO when used alone include tiredness, muscle or bone pain, rash, diarrhea, and low levels of red blood cells (anemia). The most common side effects of LIBTAYO when ...

Sanofi's rash of dealmaking has continued with a $ ... are spearheaded by its Regeneron-partnered PD-1 checkpoint inhibitor Libtayo (cemiplimab), which still has modest sales, and the drugmaker ...

In response, the body prioritizes central blood volume by reducing circulation to the skin, which can result in a purple-red rash appearing on the cheeks and the bridge of the nose. Shaped ...

Parents are heartbroken as a beloved nappy rash cream - Metanium Nappy Rash Ointment - is discontinued. The product, known for its quick healing properties, has been a staple in changing bags for ...

Adult diaper rash can develop when wearing adult diapers, incontinence briefs, or pads. It typically begins as small, inflamed patches of irritated skin and progresses to larger patches of raised ...

A ~$4.5B share repurchase program adds further value. LIBTAYO demonstrated massive growth, accelerating to 50% in Q4 2024 versus Q4 2023. Approval in CSCC means that this growth catalyst is ...

In the fourth quarter of 2024, Libtayo grew sales 50% to $367 million, propelling the PD-1 treatment past the blockbuster threshold for the first time. During the full year, the drug's sales reach ...

The C-POST study involved 415 patients who were randomized to receive either Libtayo or a placebo for up to 48 weeks. The primary measure of success, disease-free survival (DFS), showed ...